Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Pfizer Inc. (PFE): Pharma Stock Could Make Traders 122% on a Catch-up Rally

Page 1 of 2

Momentum is an important attribute when picking stocks to trade, and the strength of the price movement is something you want to embrace, not fight against.

One of the strongest market sectors so far in 2013 has been pharmaceuticals. The SPDR S&P Pharmaceuticals (ETF) (NYSE:XPH) has gained more than 30% year to date, double the gains of the S&P 500.

Not all pharma stocks have fared so well, though. Pfizer Inc. (NYSE:PFE) is only up 11% year to date, lagging the broader market and sharply behind its peers.

XHP vs PFE Chart

On the chart below, we can see that the January breakout above $27 held on the June and July pullbacks, forming a key support level. The $4 range between the $27 breakout level and the $31 yearly highs targets a breakout move to $35.

PFE Chart

The $35 target is about 22% higher than current prices, but traders who use a capital-preserving, stock substitution strategy could more than double their money on a move to that level.

One major advantage of using long call options rather than buying a stock outright is putting up much less capital to control 100 shares — that’s the power of leverage. But with all of the potential strike and expiration combinations, choosing an option can be a daunting task.

Simply put, you want to buy a high-probability option that has enough time to be right, so there are two rules traders should follow:

Rule One: Choose an option with a delta of 70 or above.

An option’s strike price is the level at which the options buyer has the right to purchase the underlying stock or ETF without any obligation to do so. (In reality, you rarely convert the option into shares, but rather simply sell back the option you bought to exit the trade for a gain or loss.)

It is important to buy options that pay off from a modest price move in the underlying stock or ETF rather than those that only make money on the infrequent price explosion. In-the-money options are more expensive, but they’re worth it, as your chances of success are mathematically superior to buying cheap, out-of-the-money options that rarely pay off.

The options Greek delta approximates the odds that an option will be in the money at expiration. It is a measurement of how well an option follows the movement in the underlying security. You can find an option’s delta using an options calculator, such as the one offered by the CBOE.

With Pfizer Inc. (NYSE:PFE) trading at about $28.80 at the time of this writing, an in-the-money $25 strike call option currently has $3.80 in real or intrinsic value. The remainder of the premium is the time value of the option. And this call option currently has a delta of about 76.

Page 1 of 2